Urothelial Cancer

The FDA has approved neoadjuvant/adjuvant enfortumab vedotin plus pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer.

Joaquim Bellmunt, MD, PhD, discusses the efficacy data seen with ctDNA-guided adjuvant atezolizumab in MIBC.

Dr Terris discusses how the early diagnosis of bladder cancer presents a challenge, particularly in female patients, who are frequently diagnosed later.

Joaquim Bellmunt, MD, PhD, discusses the phase 3 IMvigor011 trial of ctDNA-guided adjuvant atezolizumab in MIBC.

Dr Terris discusses disparities in treatment and outcomes for women with bladder cancer and summarized reasons for this poor prognosis.

Findings from the preliminary cohort show 3- and 6-month CR rates of 56% and 62%, respectively, with detalimogene in this patient population.

OncLive partnered with Two Onc Docs to review updates from the 2025 ESMO Congress on bladder cancer management that may change guidelines.

The FDA clears subcutaneous daratumumab in smoldering myeloma, adds REMS guidelines for pexidartinib in TGCT, and more.

UGN-103 produced a 77.8% 3-month CR rate in patients with low-grade, intermediate-risk NMIBC.

Shilpa Gupta, MD, discusses data from a subgroup analysis of the phase 3 JAVELIN Bladder 100 and future questions surrounding the use of avelumab maintenance in this setting.

Amit Mehta, MD, discusses practice-changing urothelial carcinoma data that have been presented throughout 2024 and 2025.

Vepugratinib-based treatment was safe and active in FGFR3-altered metastatic urothelial cancer.

Experts highlight how precision medicine, biomarkers, and targeted combinations presented at ESMO 2025 are shaping the future of GU cancer treatment.

PlasmaSure received FDA breakthrough device designation for low- to intermediate-risk non–muscle-invasive bladder cancer.

Joaquim Bellmunt, MD, PhD, discusses ways that ctDNA tests could augment bladder cancer management and the need for confirmatory data from ongoing trials.

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

Joaquim Bellmunt, MD, PhD, discusses the rationale for and findings from the IMvigor011 trial of ctDNA-guided adjuvant atezolizumab vs placebo in MIBC.

Three cycles of platinum-based chemotherapy yielded superior PROs vs 6 cycles in advanced urothelial cancer.

The FDA granted priority review to enfortumab vedotin plus pembrolizumab as perioperative therapy for cisplatin-ineligible muscle-invasive bladder cancer.

Atezolizumab plus BCG did not extend EFS vs BCG alone in BCG-naive, high-risk non–muscle invasive bladder cancer.

Adjuvant atezolizumab improved DFS and OS in patients with muscle-invasive bladder cancer who tested positive for ctDNA after radical cystectomy.

Frontline disitamab vedotin plus toripalimab significantly improved PFS and OS in HER2-expressing locally advanced or metastatic urothelial carcinoma.

Enfortumab vedotin plus pembrolizumab significantly improved survival and pCR vs surgery alone in cisplatin-ineligible MIBC per KEYNOTE-905 data.

Datopotamab deruxtecan plus rilvegostomig was active in cisplatin-ineligible and platinum-pretreated locally advanced or metastatic urothelial cancer.

SunRISe-4 data show that TAR-200 and cetrelimab led to a high pCR and 12-month RFS rate in muscle-invasive bladder cancer.